LONDON — British regulators have accused Actavis UK of charging excessive and unfair prices after the pharmaceutical company increased the price of some hydrocortisone tablets by more than 12,000 percent.

The Competition and Markets Authority said Friday that Actavis UK raised the price of its generic 10 mg hydrocortisone tablets to $110 per pack by March of 2016 from the 70 pence that another company charged for a branded product prior to April 2008. While branded drugs are subject to price regulation, generics are not.

“We allege that the company has taken advantage of this situation and the removal of the drug from price regulation, leaving the (National Health Service) – and ultimately the taxpayer – footing the bill for the substantial price rises,” the authority said.

The findings are still provisional.

Actavis UK was acquired by Israel-based Teva Pharmaceutical Industries in August.

Only subscribers are eligible to post comments. Please subscribe or to participate in the conversation. Here’s why.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.